文献速递白血病MDS 与骨髓增殖性肿瘤

靶向去泛素化酶JOSD1降解突变JAK2治疗白血病

Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.
PubMed 文献 · Leukemia · 2021-07-29

该研究通过化学遗传学筛选发现去泛素化酶JOSD1是突变JAK2的新型调控因子,JOSD1与JAK2-V617F相互作用并使其稳定,失活JOSD1可增加JAK2-V617F泛素化水平、缩短其蛋白半衰期并导致JAK2-V617F阳性原代AML细胞死亡,为MPN提供选择性靶向突变JAK2信号的新策略。

要点

  • JOSD1是突变JAK2的新型调控因子,可与JAK2-V617F相互作用并使其稳定。
  • 失活JOSD1通过增加JAK2-V617F泛素化水平缩短其蛋白半衰期。
  • 靶向JOSD1可导致JAK2-V617F阳性原代AML细胞死亡。

核心结论

  • 靶向去泛素化酶JOSD1可选择性降解突变JAK2,为MPN提供新型治疗策略。

研究设计与样本

  • 研究采用化学遗传学筛选,随后进行广泛的选择性分析和遗传学研究。

主要发现

  • JOSD1与JAK2-V617F相互作用并使其稳定。
  • 失活JOSD1导致JAK2-V617F泛素化水平增加、蛋白半衰期缩短并被降解。
  • 靶向JOSD1导致JAK2-V617F阳性原代AML细胞死亡。

临床怎么用

  • 靶向JOSD1可在保留非突变JAK2的同时选择性降解突变JAK2,有望克服JAK2激酶抑制剂的毒性限制和耐药问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in the Janus Kinase 2 (JAK2) gene resulting in constitutive kinase activation represent the most common genetic event in myeloproliferative neoplasms (MPN), a group of diseases involving overproduction of one or more kinds of blood cells, including red cells, white cells, and platelets. JAK2 kinase inhibitors, such as ruxolitinib, provide clinical benefit, but inhibition of wild-type (wt) JAK2 limits their clinical utility due to toxicity to normal cells, and small molecule inhibition of mutated JAK2 kinase activity can lead to drug resistance. Here, we present a strategy to target mutated JAK2 for degradation, using the cell's intracellular degradation machinery, while sparing non-mutated JAK2. We employed a chemical genetics screen, followed by extensive selectivity profiling and genetic studies, to identify the deubiquitinase (DUB), JOSD1, as a novel regulator of mutant JAK2. JOSD1 interacts with and stabilizes JAK2-V617F, and inactivation of the DUB leads to JAK2-V617F protein degradation by increasing its ubiquitination levels, thereby shortening its protein half-life. Moreover, targeting of JOSD1 leads to the death of JAK2-V617F-positive primary acute myeloid leukemia (AML) cells. These studies provide a novel therapeutic approach to achieving selective targeting of mutated JAK2 signaling in MPN.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Yang J, Weisberg EL, Liu X, et al. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia. 2021. PMID: 34326465. doi:10.1038/s41375-021-01336-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。